News Archives | Page 12 of 18 | Aurobindo Pharma USA

Currently Browsing

All News

January 12, 2022


Aurobindo Receives FDA Approval for Nebivolol Tablets, 2.5mg, 5mg, 10mg, and 20mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Nebivolol Tablets, 2.5mg, 5mg, 10mg, and 20mg . Aurobindo Pharma’s Nebivolol Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Bystolic® Tablets, of Allergan Sales, LLC. Nebivolol Tablets are […]

November 17, 2021


Aurobindo Receives FDA Approval for Prednisone Tablets USP, 1mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Prednisone Tablets USP, 1mg. Aurobindo Pharma’s Prednisone Tablets USP, 1mg, are an AB-rated generic equivalent to the reference listed drug (RLD), Meticorten® Tablets, of Schering Corp Sub Schering Plough Corp. Prednisone Tablets are […]

September 30, 2021


Aurobindo Receives FDA Approval for Vigabatrin for Oral Solution USP, 500mg

East Windsor, N.J. –Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Vigabatrin for Oral Solution USP, 500 mg . Aurobindo Pharma’s Vigabatrin for Oral Solution USP, 500 mg are an AB-rated generic equivalent to the reference listed drug (RLD), Sabril for Oral Solution of […]

September 23, 2021


Aurobindo Receives FDA Approval for Fenofibrate Capsules, 67mg, 134mg, and 200mg

East Windsor, N.J. –Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Fenofibrate Capsules USP, 67mg, 134mg, and 200mg. Aurobindo Pharma’s Fenofibrate Capsules USP, 67mg, 134mg, and 200mg are an AB-rated generic equivalent to the reference listed drug (RLD), Tricor Capsules of AbbVie, Inc. Fenofibrate […]

August 11, 2021


Aurobindo Receives FDA Approval for Memantine Hydrochloride Extended-Release Capsules, 7mg, 14mg, 21mg, and 28mg

East Windsor, N.J. –Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Memantine Hydrochloride Extended-Release Capsules, 7mg, 14mg, 21mg, and 28mg. Aurobindo Pharma’s Memantine Hydrochloride Extended-Release Capsules, 7mg, 14mg, 21mg, and 28mg are an AB-rated generic equivalent to the reference listed drug (RLD), Namenda XR […]

July 21, 2021


Aurobindo Receives FDA Approval for Nifedipine Extended-Release Tablets USP, 30mg, 60mg, and 90mg

East Windsor, N.J. –Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Nifedipine Extended-Release Tablets USP, 30 mg, 60mg and 90 mg. Aurobindo Pharma’s Nifedipine Extended-Release Tablets, 30 mg, 60mg, and 90 mg are an AB-rated generic equivalent to the reference listed drug (RLD), ADALAT® CC of Alvogen […]

July 15, 2021


Aurobindo Receives FDA Approval for Baclofen Tablets USP, 10 mg and 20 mg

East Windsor, N.J. –Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Baclofen Tablets USP, 10 mg and 20 mg. Aurobindo Pharma’s Baclofen Tablets USP, 10 mg and 20 mg are an AB-rated generic equivalent to the reference listed drug (RLD), LIORESAL® marketed by Novartis […]

May 17, 2021


Aurobindo Receives FDA Approval for Dorzolamide HCl and Timolol Maleate Ophthalmic Solution, 2%/0.5% (10mL bottles)

East Windsor, N.J. –Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Dorzolamide HCl and Timolol Maleate Ophthalmic Solution, 2% / 0.5% (10 mL bottles). Aurobindo Pharma’s Dorzolamide HCl and Timolol Maleate Ophthalmic Solution, are an AT-rated generic equivalent to the reference listed drug (RLD), […]

April 05, 2021


Aurobindo Receives FDA Approval for Potassium Chloride Extended-Release Tablets USP, 10 mEq, 15 mEq, and 20 mEq

East Windsor, N.J. –Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Potassium Chloride Extended-Release Tablets USP, 10 mEq, 15 mEq, and 20 mEq. Aurobindo Pharma’s Potassium Chloride Extended Release Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Potassium Chloride Extended […]

March 29, 2021


Aurobindo Receives FDA Approval for Leflunomide Tablets USP, 10 mg and 20 mg

East Windsor, N.J. –Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Leflunomide Tablets USP, 10 mg and 20 mg. Aurobindo Pharma’s Leflunomide Tablets USP, are an AB-rated generic equivalent to the reference listed drug (RLD), Arava® Tablets marketed by Sanofi-aventis U.S. LLC. Leflunomide Tablets […]

February 18, 2021


Aurobindo Receives FDA Approval for Droxidopa Capsules, 100mg, 200mg, and 300mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Droxidopa Capsules, 100mg, 200mg, and 300mg. Aurobindo Pharma’s Droxidopa Capsules, 100mg, 200mg, and 300mg are an AB-rated generic equivalent to the reference listed drug (RLD), Northera® Capsules 100mg, 200mg, and 300mg marketed by Lundbeck NA Ltd.  Droxidopa Capsules are […]

January 25, 2021


Aurobindo received FDA Approval for Tobramycin Inhalation Solution, 300 mg/5 mL

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Tobramycin Inhalation Solution, 300 mg/5 mL. Aurobindo Pharma’s Tobramycin Inhalation Solution, 300 mg/5 mL are an AB-rated generic equivalent to the reference listed drug (RLD), Tobi® Inhalation Solution, 300 mg/5 mL marketed […]